Long-term Humoral Immune Dynamics After SARS-CoV-2 Vaccination and Infection in Healthcare Workers: The VaCoMRI Study
Tekinsoy, M.; Merdan, O.; Rusen, R.; Christa, C.; Müller, K.; Priller, A.; Mijocevic, H.; Roggendorf, H.; Zelger, O.; Tinnefeld, K.; Jeske, S.; Vasilev, D.; Yazici, S.; Erber, J.; Hoffmann, D.; Knolle, P.; Protzer, U.
Show abstract
ObjectivesThe VaCoMRI study tracked a healthcare worker cohort from 2020 through June 2024 to characterize the long-term sustainability of vaccine- and infection-induced SARS-CoV-2 immunity. MethodsFollowing an initial anti-nucleocapsid (N) IgG screening of 4,554 employees in early 2020, participants were monitored regularly from the BNT162b2 rollout (December 2020). Serum collected at predefined intervals after vaccination and breakthrough infection (BTI) was analyzed for anti-N, quantitative anti-spike (anti-S) IgG, and surrogate viral neutralizing antibody (sVNT) titers. ResultsOver a median follow-up of 1,180 days, 142 healthcare workers contributed longitudinal samples; 66.2% experienced one BTI and 14.1% a second. In previously seronegative individuals, anti-N titers decreased 2.3-fold between 3 and 6 months post-first BTI, with seropositivity dropping from 82% to 40.4% (median time to seronegativity: 179 days). Conversely, prior anti-N seropositivity was associated with 4.5-fold higher anti-N IgG levels during follow-up, and a second BTI led to 3-fold higher titers at 3 months. Before BTI, the third vaccine dose significantly enhanced antibody persistence versus the second dose; at 9 months, titers remained 7.2-fold higher for sVNT and 3.9-fold higher for anti-S IgG. Initial seropositivity also predicted 2.9-fold higher sVNT levels during follow-up. ConclusionsRepeated vaccination and infection synergistically induced robust, durable spike-directed hybrid immunity. Conversely, rapid anti-N IgG waning severely limits its reliability for the retrospective serosurveillance of SARS-CoV-2 exposure in occupational settings.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Effect of booster vaccination against Delta and Omicron variants in Iceland 94%
- Waning of SARS-CoV-2 antibodies targeting the Spike protein in individuals post second dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and risk of breakthrough infections: analysis of the Virus Watch community cohort 94%
- Omicron COVID-19 Immune Correlates Analysis of a Third Dose of mRNA-1273 in the COVE Trial 94%
Similar papers in this journal
- Antibody responses following COVID-19 vaccination and breakthrough infections in naive and convalescent individuals suggests imprinting to the ancestral strain of SARS-CoV-2 95%
- Broad neutralization of SARS-CoV-2 variants, including omicron, following breakthrough infection with delta in COVID-19 vaccinated individuals 94%
- Antibody and memory B-cell immunity in a heterogeneously SARS-CoV-2 infected and vaccinated population 94%
Similar papers in this journal
- Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection 95%
- Long-lasting neutralizing antibody responses in SARS-CoV-2 seropositive individuals are robustly boosted by immunization with the CoronaVac and BNT162b2 vaccines 94%
- Antibody Responses After a Single Dose of ChAdOx1 nCoV-19 Vaccine in Healthcare Workers Previously Infected with SARS-CoV-2 94%
Similar papers in this journal
- Protection against Omicron re-infection conferred by prior heterologous SARS-CoV-2 infection, with and without mRNA vaccination 94%
- Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report 93%
- A Phase 1: Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine-BBV152 92%
Similar papers in this journal
- Correlation between post-vaccination titres of combined IgG, IgA, and IgM anti-Spike antibodies and protection against breakthrough SARS-CoV-2 infection: a population-based longitudinal study (COVIDENCE UK) 94%
- Anti-membrane and anti-spike antibodies are long-lasting and together discriminate between past COVID-19 infection and vaccination 94%
- People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.